TY - JOUR
T1 - Surgical treatment of colorectal liver metastases
AU - Cooper, Amanda B.
AU - Curley, Steven A.
N1 - Publisher Copyright:
© Chinese Clinical Oncology.
PY - 2013
Y1 - 2013
N2 - The incidence of colorectal cancer is rising in China. Since nearly 50% of these patients will ultimately develop liver metastases, an understanding of the surgical management of hepatic metastases is important. Surgical strategies for the management of liver metastases have evolved in recent years and now include adjunctive procedures such as portal vein embolization and radiofrequency ablation, which can help increase the number of patients eligible for potentially curative surgical management. In addition, innovations in treatment sequencing, including the use of peri-operative chemotherapy and the liver-first approach to the management of synchronous liver metastases have helped improve outcomes in these patients. Along with such changes in surgical management come new risks, such as chemotherapy-induced liver damage, with which the surgeon must be prepared to contend.
AB - The incidence of colorectal cancer is rising in China. Since nearly 50% of these patients will ultimately develop liver metastases, an understanding of the surgical management of hepatic metastases is important. Surgical strategies for the management of liver metastases have evolved in recent years and now include adjunctive procedures such as portal vein embolization and radiofrequency ablation, which can help increase the number of patients eligible for potentially curative surgical management. In addition, innovations in treatment sequencing, including the use of peri-operative chemotherapy and the liver-first approach to the management of synchronous liver metastases have helped improve outcomes in these patients. Along with such changes in surgical management come new risks, such as chemotherapy-induced liver damage, with which the surgeon must be prepared to contend.
UR - http://www.scopus.com/inward/record.url?scp=84959927072&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959927072&partnerID=8YFLogxK
U2 - 10.3978/j.issn.2304-3865.2013.03.02
DO - 10.3978/j.issn.2304-3865.2013.03.02
M3 - Review article
AN - SCOPUS:84959927072
SN - 2304-3865
VL - 2
JO - Chinese clinical oncology
JF - Chinese clinical oncology
IS - 2
ER -